Phillip Thomas Hawkins

Phillip Thomas Hawkins

Auto-generated profile, based on publicly available information

Phillip Thomas Hawkins

Babraham Institute, Cambridge, UK

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 1997 in Science
Verified
Journal Article
Closed access
PDF file
DSDavid Stokoe
David Stokoe
LSLeonard R. Stephens
Leonard R. Stephens
TCTerry Copeland
Terry Copeland
PGPiers R. J. Gaffney
Piers R. J. Gaffney
CRColin B. Reese
Colin B. Reese
PHPhillip T. Hawkins
Phillip T. Hawkins
Protein kinase B (PKB) is a proto-oncogene that is activated in signaling pathways initiated by phosphoinositide 3-kinase. Chromatographic separation of brain cytosol revealed a kinase activity that phosphorylated and activated PKB only in the presence of phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P 3 ]. Phosphorylation occurred exclusively on threonine-308, a residue implicated in activation of PKB in vivo. PtdIns(3,4,5)P 3 was determined to have a dual role: Its binding to the pleckstrin homology domain of PKB was required to allow phosphorylation by the upstream kinase and it directly activated the upstream kinase.

23 February 2012 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
BVBart Vanhaesebroeck
Bart Vanhaesebroeck
LSLen Stephens
Len Stephens
PHPhillip Hawkins
Phillip Hawkins

30 January 1998 in Science
Verified
Journal Article
Closed access
PDF file
LSLen Stephens
Len Stephens
KAKaren Anderson
Karen Anderson
DSDavid Stokoe
David Stokoe
HEHediye Erdjument-Bromage
Hediye Erdjument-Bromage
GPGavin F. Painter
Gavin F. Painter
PHPhillip T. Hawkins
Phillip T. Hawkins
Protein kinase B (PKB) is activated in response to phosphoinositide 3-kinases and their lipid products phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P 3 ] and PtdIns(3,4)P 2 in the signaling pathways used by a wide variety of growth factors, antigens, and inflammatory stimuli. PKB is a direct target of these lipids, but this regulation is complex. The lipids can bind to the pleckstrin homologous domain of PKB, causing its translocation to the membrane, and also enable upstream, Thr 308 -directed kinases to phosphorylate and activate PKB. Four isoforms of these PKB kinases were purified from sheep brain. They bound PtdIns(3,4,5)P 3 and associated with lipid vesicles containing it. These kinases contain an NH 2 -terminal catalytic domain and a COOH-terminal pleckstrin homologous domain, and their heterologous expression augments receptor activation of PKB, which suggests they are the primary signal transducers that enable PtdIns(3,4,5)P 3 or PtdIns- (3,4)P 2 to activate PKB and hence to control signaling pathways regulating cell survival, glucose uptake, and glycogen metabolism.

15 November 2013 in Science
Verified
Journal Article
Closed access
PDF file
IAIvan Angulo
Ivan Angulo
OVOscar Vadas
Oscar Vadas
FGFabien Garçon
Fabien Garçon
EBEdward Banham-Hall
Edward Banham-Hall
VPVincent Plagnol
Vincent Plagnol
SNSergey Nejentsev
Sergey Nejentsev
Answers from Exomes: Exome sequencing, which targets only the protein-coding regions of the genome, has the potential to identify the underlying genetic causes of rare inherited diseases. Angulo et al. (p. 866 , published online 17 October; see Perspective by Conley and Fruman ) performed exome sequencing of individuals from seven unrelated families with severe, recurrent respiratory infections. The patients carried the same mutation in the gene coding for the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ). The mutation caused aberrant activation of this kinase, which plays a key role in immune cell signaling. Drugs inhibiting PI3Kδ are already in clinical trials for other disorders.

1 December 2000 in Cell
Verified
Journal Article
Closed access
MPMichael E. Pacold
Michael E. Pacold
SSSabine Suire
Sabine Suire
OPOlga Perisic
Olga Perisic
SLSamuel Lara-Gonzalez
Samuel Lara-Gonzalez
CDColin T. Davis
Colin T. Davis
RWRoger L. Williams
Roger L. Williams

1 June 2015 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Open access
PHP.T. Hawkins
P.T. Hawkins
LSL.R. Stephens
L.R. Stephens
PI3Ks regulate several key events in the inflammatory response to damage and infection. There are four Class I PI3K isoforms (PI3Kα,β,γ,δ), three Class II PI3K isoforms (PI3KC2α, C2β, C2γ) and a single Class III PI3K. The four Class I isoforms synthesise the phospholipid 'PIP3'. PIP3 is a 'second messenger' used by many different cell surface receptors to control cell movement, growth, survival and differentiation. These four isoforms have overlapping functions but each is adapted to receive efficient stimulation by particular receptor sub-types. PI3Kγ is highly expressed in leukocytes and plays a particularly important role in chemokine-mediated recruitment and activation of innate immune cells at sites of inflammation. PI3Kδ is also highly expressed in leukocytes and plays a key role in antigen receptor and cytokine-mediated B and T cell development, differentiation and function. Class III PI3K synthesises the phospholipid PI3P, which regulates endosome-lysosome trafficking and the induction of autophagy, pathways involved in pathogen killing, antigen processing and immune cell survival. Much less is known about the function of Class II PI3Ks, but emerging evidence indicates they can synthesise PI3P and PI34P2 and are involved in the regulation of endocytosis. The creation of genetically-modified mice with altered PI3K signalling, together with the development of isoform-selective, small-molecule PI3K inhibitors, has allowed the evaluation of the individual roles of Class I PI3K isoforms in several mouse models of chronic inflammation. Selective inhibition of PI3Kδ, γ or β has each been shown to reduce the severity of inflammation in one or more models of autoimmune disease, respiratory disease or allergic inflammation, with dual γ/δ or β/δ inhibition generally proving more effective. The inhibition of Class I PI3Ks may therefore offer a therapeutic opportunity to treat non-resolving inflammatory pathologies in humans. This article is part of a Special Issue entitled Phosphoinositides.